Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$64 Mln
P/E Ratio
--
P/B Ratio
0.42
Industry P/E
--
Debt to Equity
0.1
ROE
-0.6 %
ROCE
-56.64 %
Div. Yield
0 %
Book Value
3.04
EPS
-2.31
CFO
$-186.18 Mln
EBITDA
$-236.04 Mln
Net Profit
$-225.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cabaletta Bio (CABA)
| -42.29 | -18.63 | -43.04 | -88.10 | -1.48 | -28.68 | -- |
|
BSE Sensex*
| 2.66 | 3.76 | 5.83 | 8.95 | 11.77 | 20.12 | 11.36 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Cabaletta Bio (CABA)
| -89.81 | 145.41 | 144.06 | -69.63 | -10.67 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory... domain-containing fully human CD19-CAR T for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Address: 2929 Arch Street, Philadelphia, PA, United States, 19104 Read more
Co-Founder, Chairman, CEO & President
Dr. Steven A. Nichtberger M.D.
Co-Founder, Chairman, CEO & President
Dr. Steven A. Nichtberger M.D.
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cabaletta Bio Inc (CABA) stood at $ 185 Mln as on 31-Dec-24
The share price of Cabaletta Bio Inc (CABA) is $1.31 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Cabaletta Bio Inc (CABA) has given a return of -1.48% in the last 3 years.
Cabaletta Bio Inc (CABA) has a market capitalisation of $ 64 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cabaletta Bio Inc (CABA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cabaletta Bio Inc (CABA) and enter the required number of quantities and click on buy to purchase the shares of Cabaletta Bio Inc (CABA).
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Address: 2929 Arch Street, Philadelphia, PA, United States, 19104
The CEO & director of Dr. Steven A. Nichtberger M.D.. is Cabaletta Bio Inc (CABA), and CFO & Sr. VP is Dr. Steven A. Nichtberger M.D..
There is no promoter pledging in Cabaletta Bio Inc (CABA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Cabaletta Bio Inc. (CABA) | Ratios |
|---|---|
|
Return on equity(%)
|
-59.64
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cabaletta Bio Inc (CABA) was $0 Mln.
$0.04
(
